Sign in

CIK 0000949858

  • Non-accelerated filer
  • Smaller reporting company

ACHIEVE LIFE SCIENCES, INC.

Sign in to watch
Tickers
ACHV QUIT
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
954343413
Phone
+1 425-686-1500
Business address
22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
Former names
ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC

Securities

  • ACHV Common stock Nasdaq
  • QUIT Common Shares Nasdaq
  1. 4 Exercise or conversion Director acquired 21,130 shares (option exercise)
  2. 4 Exercise or conversion President and CEO acquired 871 shares (option exercise)
  3. 4 Open-market sale 10% owner sold 100,000 shares at $20.79 ($2,078,610)
  4. 4 Open-market sale 10% owner sold 88,400 shares at $21.41 ($1,892,290)
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4/A Derivatives Options or other derivatives
  11. 4/A Derivatives Options or other derivatives
  12. 4/A Derivatives Options or other derivatives
  13. 4/A Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Exercise or conversion President and CEO acquired 24,809 shares (option exercise)
  18. 4 Open-market sale 10% owner sold 450,000 shares at $5.95 ($2,677,500)
  19. 4/A Open-market buy CFO and Secretary bought 10,000 shares at an average $6.77 ($67,700)
  20. 4/A Open-market buy CFO and Secretary bought 3,000 shares at an average $2.43 ($7,278)

Page 19 of 24 · 465 filings